KW-5805

KW-5805 (30 mg/kg; p.o.) significantly increases the amount of mucus adhering to gastric mucosa, the hexose content of mucosal glycoproteins, and the activity of glucosamine synthetase in male Donryu rats^[1].
KW-5805 (10-30 mg/kg; p.o.) significantly maintains gastric mucosal blood volume and oxygen supply adequacy during hemorrhagic shock, while the 30 mg/kg oral dose significantly alleviates ischemia-reperfusion-induced gastric mucosal vascular injury in male Donryu rats^[1].
KW-5805 (p.o.) potently inhibits water immersion stress-induced gastric ulcers in male Donryu rats with an ED₅₀ of 3.5 mg/kg; potently inhibits aspirin-induced gastric ulcers with an ED₅₀ of 1.2 mg/kg; potently inhibits indomethacin-induced gastric ulcers with an ED₅₀ of 10.0 mg/kg; potently inhibits mepirizole-induced duodenal ulcers with an ED₅₀ of 6.8 mg/kg; potently inhibits 0.6 N HCl-induced gastric mucosal lesions with an oral ED₅₀ of 39.8 mg/kg; and potently inhibits acidified taurocholate-induced gastric mucosal lesions with an oral ED₅₀ of 11.8 mg/kg^[2].
KW-5805 (4.5-10 mg/kg; p.o., s.c.) potently inhibits gastric mucosal injury induced by 99.5% ethanol in male Donryu rats, with an oral ED₅₀ of 4.5 mg/kg, and oral or subcutaneous administration at a dose of 10 mg/kg significantly alleviates the injury^[2].
KW-5805 (3-30 mg/kg; intradermal injection) slightly inhibits gastric acid secretion in pylorus-ligated male Donryu rats, and at the dose of 30 mg/kg i.d., it significantly reduces gastric juice volume and acid output by 30%^[2].
KW-5805 (10-30 mg/kg; intravenous administration) significantly inhibits acetylcholine- and tetragastrin-stimulated gastric acid secretion in male Donryu rats with acute gastric fistula^2].